124 related articles for article (PubMed ID: 26258485)
1. HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.
Pernas M; Sanchez-Merino V; Casado C; Merino-Mansilla A; Olivares I; Yuste E; Lopez-Galindez C
PLoS One; 2015; 10(8):e0134054. PubMed ID: 26258485
[TBL] [Abstract][Full Text] [Related]
2. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.
Ferreira CB; Merino-Mansilla A; Llano A; Pérez I; Crespo I; Llinas L; Garcia F; Gatell JM; Yuste E; Sanchez-Merino V
J Virol; 2013 Nov; 87(22):12227-36. PubMed ID: 24006439
[TBL] [Abstract][Full Text] [Related]
3. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
[TBL] [Abstract][Full Text] [Related]
4. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
6. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
[TBL] [Abstract][Full Text] [Related]
7. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
[TBL] [Abstract][Full Text] [Related]
8. Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.
Hao Y; Bai G; Wang J; Zhao L; Sutherland K; Cai J; Cao C
BMC Immunol; 2015 Apr; 16():25. PubMed ID: 25927639
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of HIV-1 dual infection in long-term nonprogressor-elite controllers.
Pernas M; Casado C; Sandonis V; Arcones C; Rodríguez C; Ruiz-Mateos E; Ramírez de Arellano E; Rallón N; Del Val M; Grau E; López-Vazquez M; Leal M; Del Romero J; López Galíndez C
J Acquir Immune Defic Syndr; 2013 Nov; 64(3):225-31. PubMed ID: 23714744
[TBL] [Abstract][Full Text] [Related]
10. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
[TBL] [Abstract][Full Text] [Related]
11. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.
Mahalanabis M; Jayaraman P; Miura T; Pereyra F; Chester EM; Richardson B; Walker B; Haigwood NL
J Virol; 2009 Jan; 83(2):662-72. PubMed ID: 18987151
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
[TBL] [Abstract][Full Text] [Related]
13. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
14. Similar neutralizing activity in the HIV-1 infected long term non-progressors(LTNPs) and typical progressors(TPs).
Wang Z; Li TY; Li JY; Chen LL; Liu YJ; Li HP; Bao ZY; Wang XL; Zhuang DM; Liu SY; Li L
Virol Sin; 2012 Jun; 27(3):165-71. PubMed ID: 22684470
[TBL] [Abstract][Full Text] [Related]
15. Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers.
Casado C; Marrero-Hernández S; Márquez-Arce D; Pernas M; Marfil S; Borràs-Grañana F; Olivares I; Cabrera-Rodríguez R; Valera MS; de Armas-Rillo L; Lemey P; Blanco J; Valenzuela-Fernández A; Lopez-Galíndez C
mBio; 2018 Apr; 9(2):. PubMed ID: 29636433
[TBL] [Abstract][Full Text] [Related]
16. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
[TBL] [Abstract][Full Text] [Related]
17. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
[TBL] [Abstract][Full Text] [Related]
18. Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.
Bandawe GP; Moore PL; Werner L; Gray ES; Sheward DJ; Madiga M; Nofemela A; Thebus R; Marais JC; Maboko L; Abdool Karim SS; Hoelscher M; Morris L; Williamson C
J Infect Dis; 2015 May; 211(9):1461-6. PubMed ID: 25398460
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
Pilgrim AK; Pantaleo G; Cohen OJ; Fink LM; Zhou JY; Zhou JT; Bolognesi DP; Fauci AS; Montefiori DC
J Infect Dis; 1997 Oct; 176(4):924-32. PubMed ID: 9333150
[TBL] [Abstract][Full Text] [Related]
20. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
